Glucotrack (GCTK) Notes Payables (2010 - 2026)

Glucotrack's (GCTK) quarterly Notes Payables came in at $1.7 million in Q2 2026, down 46.83% quarter-over-quarter from $3.2 million in Q4 2025.

Analysis

Glucotrack (GCTK) Notes Payables (2010 - 2026) Analysis & Trends

Glucotrack (GCTK) has reported Notes Payables for 7 consecutive years, with $1.7 million the latest figure, recorded in Q2 2026.

For the quarter ending Q2 2026, Notes Payables changed N/A year-over-year to $1.7 million; the trailing twelve-month figure through Jun 2026 stood at $1.7 million (changed N/A YoY), and the FY2025 full-year result was $3.2 million, up 63540.0% from the prior year.
Notes Payables eased to $1.7 million in Q2 2026 per GCTK's latest filing, from $3.2 million in the prior quarter.
Across five years, Notes Payables topped out at $3.2 million in Q4 2025 and bottomed at $5000.0 in Q3 2024.
Historically, Notes Payables has averaged $1.1 million across 3 years, with a median of $12000.0 in 2024.
The widest YoY moves for Notes Payables: up 63540.0% in 2025, down 60520.0% in 2025.
Over 3 years, Notes Payables stood at $5000.0 in 2024, then surged by 63540.0% to $3.2 million in 2025, then slumped by 46.83% to $1.7 million in 2026.
According to Business Quant data, Notes Payables over the past three periods registered $1.7 million, $3.2 million, and $3.0 million for Q2 2026, Q4 2025, and Q3 2025 respectively.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	180.78 Bn	175.17 Bn	7.27 Bn
2	Intuitive Surgical	127.04 Bn	121.82 Bn	1.96 Bn
3	Medtronic	117.04 Bn	108.22 Bn	6.34 Bn
4	Stryker	103.86 Bn	100.38 Bn	4.50 Bn
5	Boston Scientific	63.50 Bn	62.96 Bn	3.85 Bn
6	Edwards Lifesciences	49.74 Bn	45.49 Bn	1.35 Bn
7	Alcon	32.99 Bn	31.53 Bn	1.68 Bn
8	Dexcom	32.12 Bn	30.17 Bn	830.00 Mn
9	Steris	20.69 Bn	20.21 Bn	684.20 Mn
10	Glucotrack	1.08 Mn	-45,410.46	-

Historic Data

Download Data